These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 35296300)

  • 1. HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis.
    Tan RSYC; Ong WS; Lee KH; Lim AH; Park S; Park YH; Lin CH; Lu YS; Ono M; Ueno T; Naito Y; Onishi T; Lim GH; Tan SM; Lee HB; Ryu HS; Han W; Tan VKM; Wong FY; Im SA; Tan PH; Chan JY; Yap YS
    BMC Med; 2022 Mar; 20(1):105. PubMed ID: 35296300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER2-low-positive and response to NACT and prognosis in HER2-negative non-metastatic BC.
    Li JJ; Yu Y; Ge J
    Breast Cancer; 2023 May; 30(3):364-378. PubMed ID: 36656510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical, Epidemiologic, and Pathologic Significance of ERBB2-Low Expression in Breast Cancer.
    Khoury T; Mendicino L; Payne Ondracek R; Yao S; Davis W; Omilian AR; Kwan ML; Roh JM; D'Addario L; Valice E; Fernandez D; Ergas IJ; Chua AV; Ambrosone CB; Kushi LH
    JAMA Netw Open; 2024 Mar; 7(3):e243345. PubMed ID: 38517439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of HER2-low status for patients with early-stage breast cancer and non-pCR after neoadjuvant chemotherapy: a National Cancer Database Analysis.
    Li H; Plichta JK; Li K; Jin Y; Thomas SM; Ma F; Tang L; Wei Q; He YW; Chen Q; Guo Y; Liu Y; Zhang J; Luo S
    Breast Cancer Res Treat; 2024 Feb; 204(1):89-105. PubMed ID: 38066250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Classification of HER2-negative breast cancers by
    Loh JW; Lim AH; Chan JY; Yap YS
    Ther Adv Med Oncol; 2023; 15():17588359231206259. PubMed ID: 37920257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy.
    Kang S; Lee SH; Lee HJ; Jeong H; Jeong JH; Kim JE; Ahn JH; Jung KH; Gong G; Kim HH; Lee S; Lee J; Kim SB
    Eur J Cancer; 2022 Nov; 176():30-40. PubMed ID: 36183652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer: A systematic review and meta-analysis.
    Ergun Y; Ucar G; Akagunduz B
    Cancer Treat Rev; 2023 Apr; 115():102538. PubMed ID: 36898351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer.
    de Moura Leite L; Cesca MG; Tavares MC; Santana DM; Saldanha EF; Guimarães PT; Sá DDS; Simões MFE; Viana RL; Rocha FG; Loose SK; Silva SF; Pirolli R; Fogassa CAZ; Mattos BRS; Campos FAB; Sanches SM; de Lima VCC; Pondé NF
    Breast Cancer Res Treat; 2021 Nov; 190(1):155-163. PubMed ID: 34409551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis.
    Abdel-Fatah TMA; Agarwal D; Liu DX; Russell R; Rueda OM; Liu K; Xu B; Moseley PM; Green AR; Pockley AG; Rees RC; Caldas C; Ellis IO; Ball GR; Chan SYT
    Lancet Oncol; 2016 Jul; 17(7):1004-1018. PubMed ID: 27312051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer.
    Almstedt K; Heimes AS; Kappenberg F; Battista MJ; Lehr HA; Krajnak S; Lebrecht A; Gehrmann M; Stewen K; Brenner W; Weikel W; Rahnenführer J; Hengstler JG; Hasenburg A; Schmidt M
    Eur J Cancer; 2022 Sep; 173():10-19. PubMed ID: 35839597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinicopathological features and prognosis of breast cancer with human epidermal growth factor receptor 2 low expression].
    Zhu XJ; Zhang H; Zhang S; Li D; Li X; Xu L; Li T
    Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):243-253. PubMed ID: 37042134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognosis difference between HER2-low and HER2-zero breast cancer patients: a systematic review and meta-analysis.
    Li C; Yuan Q; Deng T; Xu G; Hou J; Zheng L; Wu G
    Breast Cancer; 2023 Nov; 30(6):965-975. PubMed ID: 37470943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France.
    de Calbiac O; Lusque A; Mailliez A; Bachelot T; Uwer L; Mouret-Reynier MA; Emile G; Jouannaud C; Gonçalves A; Patsouris A; Diéras V; Leheurteur M; Petit T; Cottu P; Ferrero JM; D'Hondt V; Desmoulins I; Mourato-Ribeiro J; Martin AL; Frenel JS
    JAMA Netw Open; 2022 Sep; 5(9):e2231170. PubMed ID: 36107428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.
    Denkert C; Seither F; Schneeweiss A; Link T; Blohmer JU; Just M; Wimberger P; Forberger A; Tesch H; Jackisch C; Schmatloch S; Reinisch M; Solomayer EF; Schmitt WD; Hanusch C; Fasching PA; Lübbe K; Solbach C; Huober J; Rhiem K; Marmé F; Reimer T; Schmidt M; Sinn BV; Janni W; Stickeler E; Michel L; Stötzer O; Hahnen E; Furlanetto J; Seiler S; Nekljudova V; Untch M; Loibl S
    Lancet Oncol; 2021 Aug; 22(8):1151-1161. PubMed ID: 34252375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.
    Koutras A; Lazaridis G; Koliou GA; Kouvatseas G; Christodoulou C; Pectasides D; Kotoula V; Batistatou A; Bobos M; Tsolaki E; Papadopoulou K; Pentheroudakis G; Papakostas P; Pervana S; Petraki K; Chrisafi S; Razis E; Psyrri A; Bafaloukos D; Kalogeras KT; Kalofonos HP; Fountzilas G
    PLoS One; 2018; 13(12):e0207707. PubMed ID: 30521571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age, Body Mass Index, Tumor Subtype, and Racial and Ethnic Disparities in Breast Cancer Survival.
    Lipsyc-Sharf M; Ballman KV; Campbell JD; Muss HB; Perez EA; Shulman LN; Carey LA; Partridge AH; Warner ET
    JAMA Netw Open; 2023 Oct; 6(10):e2339584. PubMed ID: 37878313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC).
    Ferrando L; Vingiani A; Garuti A; Vernieri C; Belfiore A; Agnelli L; Dagrada G; Ivanoiu D; Bonizzi G; Munzone E; Lippolis L; Dameri M; Ravera F; Colleoni M; Viale G; Magnani L; Ballestrero A; Zoppoli G; Pruneri G
    PLoS Genet; 2023 Jan; 19(1):e1010563. PubMed ID: 36595552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
    Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
    Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients.
    Ligorio F; Zambelli L; Bottiglieri A; Castagnoli L; Zattarin E; Lobefaro R; Ottini A; Vingiani A; Pupa SM; Bianchi GV; Capri G; Pruneri G; de Braud F; Vernieri C
    Ther Adv Med Oncol; 2021; 13():17588359211006960. PubMed ID: 33948122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies.
    Carene D; Tran-Dien A; Lemonnier J; Dalenc F; Levy C; Pierga JY; Jacot W; Canon JL; Richon C; Lacroix L; Caux C; André F; Michiels S
    Breast Cancer Res Treat; 2020 Jan; 179(2):387-401. PubMed ID: 31620934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.